Dr. LAETITIA FARTOUX
Gastroenterologist and hepatologist

Career

Praticien Hospitalier plein temps titulaire à Saint-Antoine (2008 à 2015) et à La Pitié Salpêtrière depuis 2015

Chef de Clinique Assistant, service d’Hépatologie à Saint Antoine, 2004 – 2008

Années de Master et DEA, 2001 à 2004

Interne des hôpitaux de Paris 1997 – 2001

 

Publications

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus SW, Ma J, Siegel AB, Cheng AL, Kudo M; KEYNOTE-224 investigators. Lancet Oncol. 2018 Jun 1.

 

A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers. Escudier B, Faivre S, Van Cutsem E, Germann N, Pouget JC, Plummer R, Vergote I, Thistlethwaite F, Bjarnason GA, Jones R, Mackay H, Edeline J, Fartoux L, Hirte H, Oza A. Target Oncol. 2017 Oct;12(5):655-661.

 

Growth factor receptor binding protein 14 inhibition triggers insulin-induced mouse hepatocyte proliferation and is associated with hepatocellular carcinoma. Morzyglod L, Caüzac M, Popineau L, Denechaud PD, Fajas L, Ragazzon B, Fauveau V, Planchais J, Vasseur-Cognet M, Fartoux L, Scatton O, Rosmorduc O, Guilmeau S, Postic C, Desdouets C, Desbois-Mouthon C, Burnol AF. Hepatology. 2017 Apr;65(4):1352-1368.

Map my route